Q1 EPS Estimate for Nurix Therapeutics Reduced by Analyst

Nurix Therapeutics, Inc. (NASDAQ:NRIX) – Analysts at HC Wainwright dropped their Q1 2025 earnings per share (EPS) estimates for shares of Nurix Therapeutics in a research note issued to investors on Wednesday, January 29th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($0.72) per share for the quarter, down from their prior forecast of ($0.67). HC Wainwright has a “Buy” rating and a $36.00 price target on the stock. The consensus estimate for Nurix Therapeutics’ current full-year earnings is ($2.73) per share. HC Wainwright also issued estimates for Nurix Therapeutics’ Q2 2025 earnings at ($0.74) EPS, Q3 2025 earnings at ($0.76) EPS, Q4 2025 earnings at ($0.78) EPS and FY2025 earnings at ($3.00) EPS.

A number of other equities research analysts have also recently weighed in on NRIX. Needham & Company LLC cut their price target on Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating on the stock in a report on Wednesday. Royal Bank of Canada lifted their target price on Nurix Therapeutics from $26.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday. Stephens reissued an “overweight” rating and set a $31.00 price target on shares of Nurix Therapeutics in a report on Tuesday, January 21st. JPMorgan Chase & Co. cut their price objective on shares of Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating on the stock in a research note on Wednesday. Finally, Jefferies Financial Group started coverage on shares of Nurix Therapeutics in a research report on Friday, October 11th. They issued a “buy” rating and a $41.00 target price for the company. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, Nurix Therapeutics has an average rating of “Moderate Buy” and an average price target of $30.71.

Nurix Therapeutics Stock Down 1.5 %

Nurix Therapeutics stock opened at $19.71 on Friday. Nurix Therapeutics has a 52-week low of $7.79 and a 52-week high of $29.56. The firm has a market capitalization of $1.50 billion, a price-to-earnings ratio of -6.82 and a beta of 2.14. The firm has a 50-day moving average price of $20.09 and a two-hundred day moving average price of $22.39.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 63.38%.

Insider Transactions at Nurix Therapeutics

In other news, insider Gwenn Hansen sold 3,690 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $73,246.50. Following the sale, the insider now owns 55,937 shares in the company, valued at $1,110,349.45. The trade was a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Houte Hans Van sold 2,811 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $55,798.35. Following the completion of the sale, the chief financial officer now owns 39,549 shares of the company’s stock, valued at approximately $785,047.65. This trade represents a 6.64 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.20% of the company’s stock.

Institutional Trading of Nurix Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Wellington Management Group LLP lifted its position in Nurix Therapeutics by 8.8% in the 3rd quarter. Wellington Management Group LLP now owns 3,482,105 shares of the company’s stock worth $78,243,000 after buying an additional 280,240 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Nurix Therapeutics by 9.6% during the third quarter. Geode Capital Management LLC now owns 1,448,040 shares of the company’s stock worth $32,544,000 after acquiring an additional 126,306 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its position in Nurix Therapeutics by 42.7% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 789,222 shares of the company’s stock valued at $14,869,000 after purchasing an additional 235,971 shares during the last quarter. Millennium Management LLC grew its stake in Nurix Therapeutics by 60.2% in the second quarter. Millennium Management LLC now owns 599,623 shares of the company’s stock valued at $12,514,000 after purchasing an additional 225,374 shares in the last quarter. Finally, FMR LLC increased its position in Nurix Therapeutics by 675.9% in the 3rd quarter. FMR LLC now owns 586,902 shares of the company’s stock worth $13,188,000 after purchasing an additional 511,256 shares during the last quarter.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.